# Prospective Evaluation of the StatusFirst™ CHF NT-proBNP Device in Human Whole Blood and Plasma Samples

> **NCT00734045** · — · COMPLETED · sponsor: **Nanogen, Inc.** · enrollment: 450 (estimated)

## Conditions studied

- Congestive Heart Failure (CHF)

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT00734045
- **Lead sponsor:** Nanogen, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2008-11
- **Final completion:** 2008-11
- **Target enrollment:** 450 (ESTIMATED)
- **Last updated:** 2008-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00734045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00734045, "Prospective Evaluation of the StatusFirst™ CHF NT-proBNP Device in Human Whole Blood and Plasma Samples". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00734045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*